Literature DB >> 30378066

Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia.

Surendra K Shukla1, Aneesha Dasgupta2, Scott E Mulder2, Pankaj K Singh3,4,5,6.   

Abstract

Cachexia, a complex metabolic syndrome, is characterized by involuntary weight loss along with muscle wasting and fat depletion leading to poor quality of life of patients. About 80% of pancreatic cancer patients exhibit cachectic phenotype at the time of diagnosis. Here, we present the several molecular and physiological parameters, which we utilize to study the pancreatic cancer-induced cachexia in in vitro models and preclinical mice models of pancreatic cancer. We have described myotube and adipocyte-based in vitro models of muscle and fat wasting, including methods of cell culture, differentiation, and treatment with cancer cell-conditioned medium. Furthermore, we have explained the methods of evaluation of key cachectic markers for muscles. Next, we have detailed the orthotopic implantation mouse models of pancreatic cancer and evaluation of different physiological parameters, including body weight, food intake, body composition analysis, glucose tolerance test, insulin resistance test, grip strength measurement, and rotarod performance test. We have also explained morphological parameters and molecular markers to evaluate the muscle wasting in pancreatic cancer-induced cachexia.

Entities:  

Keywords:  3T3L1; C2C12; Cachexia; Fat depletion; Muscle wasting; Orthotopic implantation model; Pancreatic cancer

Mesh:

Substances:

Year:  2019        PMID: 30378066      PMCID: PMC6709446          DOI: 10.1007/978-1-4939-8879-2_28

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

Review 1.  Cachexia in cancer patients.

Authors:  Michael J Tisdale
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

Review 2.  Clinical evaluation and optimal management of cancer cachexia.

Authors:  Albert Tuca; Paula Jimenez-Fonseca; Pere Gascón
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-15       Impact factor: 6.312

Review 3.  Cachexia.

Authors:  D P Kotler
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

4.  Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation.

Authors:  Surendra Kumar Shukla; Vijay Kumar
Journal:  FEBS J       Date:  2012-09-07       Impact factor: 5.542

Review 5.  Muscle wasting in cancer.

Authors:  N Johns; N A Stephens; K C H Fearon
Journal:  Int J Biochem Cell Biol       Date:  2013-06-11       Impact factor: 5.085

6.  MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.

Authors:  Nina V Chaika; Teklab Gebregiworgis; Michelle E Lewallen; Vinee Purohit; Prakash Radhakrishnan; Xiang Liu; Bo Zhang; Kamiya Mehla; Roger B Brown; Thomas Caffrey; Fang Yu; Keith R Johnson; Robert Powers; Michael A Hollingsworth; Pankaj K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

7.  Cachexia: a problem of energetic inefficiency.

Authors:  Josep M Argilés; Cibely Cristine Fontes-Oliveira; Miriam Toledo; Francisco J López-Soriano; Sílvia Busquets
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-08-15       Impact factor: 12.910

8.  MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.

Authors:  Surendra K Shukla; Venugopal Gunda; Jaime Abrego; Dhanya Haridas; Anusha Mishra; Joshua Souchek; Nina V Chaika; Fang Yu; Aaron R Sasson; Audrey J Lazenby; Surinder K Batra; Pankaj K Singh
Journal:  Oncotarget       Date:  2015-08-07

9.  Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth.

Authors:  Surendra K Shukla; Aneesha Dasgupta; Kamiya Mehla; Venugopal Gunda; Enza Vernucci; Joshua Souchek; Gennifer Goode; Ryan King; Anusha Mishra; Ibha Rai; Sangeetha Nagarajan; Nina V Chaika; Fang Yu; Pankaj K Singh
Journal:  Oncotarget       Date:  2015-12-01

10.  Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Teklab Gebregiworgis; Vinee Purohit; Nina V Chaika; Venugopal Gunda; Prakash Radhakrishnan; Kamiya Mehla; Iraklis I Pipinos; Robert Powers; Fang Yu; Pankaj K Singh
Journal:  Cancer Metab       Date:  2014-09-01
View more
  3 in total

1.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

2.  JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.

Authors:  Scott E Mulder; Aneesha Dasgupta; Ryan J King; Jaime Abrego; Kuldeep S Attri; Divya Murthy; Surendra K Shukla; Pankaj K Singh
Journal:  Cancer Lett       Date:  2020-07-28       Impact factor: 8.679

3.  The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth.

Authors:  Ghada A Soliman; Surendra K Shukla; Asserewou Etekpo; Venugopal Gunda; Sharalyn M Steenson; Nagsen Gautam; Yazen Alnouti; Pankaj K Singh
Journal:  Curr Dev Nutr       Date:  2020-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.